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Abstract
Exosomes are 30–100 nm microvesicles which contain
complex cellular signals of RNA, protein and lipids.
Because of this, exosomes are implicated as having limitless
therapeutic potential for the treatment of cancer, pregnancy
complications, infections, and autoimmune diseases. To
date we know a considerable amount about exosome
biogenesis and secretion, but there is a paucity of data
regarding the uptake of exosomes by immune and non-
immune cell types (e.g., cancer cells) and the internal
signalling pathways by which these exosomes elicit a
cellular response. Answering these questions is of para‐
mount importance.
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1. Introduction
In the 1960s, Robert Feynman implored researchers to try
to develop nanotechnology with the ability to interact with
the human body at the cellular level [1]. Since the 1990s,
nanomedicines generated from polymeric or liposomal
nanoparticles—encapsulating or adsorbing one or more
drugs—have been assessed in clinical trials and imple‐
mented in the clinic, for the treatment of cancer, HIV/AIDS,
malaria, and tuberculosis. Biologically, exosomes offer a
viable ”natural” therapeutic avenue for immune modula‐
tion. Exosomes are nanoscale (30–100 nm) vesicles contain‐
ing lipid, protein and RNA species in a single biological
unit. They are present in the intracellular space and in body
fluids (including plasma, saliva, urine, pleural ascites,
amniotic fluid, cerebrospinal fluid, colostrum, breast milk
and semen), and may act locally or from a distance, through
the secretion of soluble factors or cell-cell contact.
Previous reviews have detailed exosome biogenesis,
composition, and the cellular response of T cells to tumour-
[2], dendritic cell (DC)- [3–5], and placenta-derived
exosomes [6]. This review highlights recent advances in
these research areas of exosome function, but focuses on
what is currently known about exosome targeting, inter‐
nalization and elimination, with specific reference to T
cells.
2. Exosome Biogenesis and Secretion
Exosome biogenesis starts with the invagination of the late
endosomal limiting membrane into the lumen to form
multi-vesicular bodies (MVBs). Consistent with the
formation of other cell-derived vesicles, the formation of
exosomes requires the evolutionarily conserved soluble N-
ethylmaleimide-sensitive factor attachment protein
receptor (SNARE), Rab, coat complex subunit and Sec 1
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proteins [7]. At this stage, MVBs contain “recycled” cell-
surface proteins, and RNA and proteins derived from the
cytoplasm. “De novo” proteins from the endoplasmic
reticulum and Golgi complex may be directly sorted into
the MVBs, guided by either (i) sequential action of the
endosomal-sorting complex required for transport
(ESCRT) machinery [8] (specifically AIP1/Alix/Vps31 and
Tsg101/Vps23 [9]), or (ii) by a ceramide/tetraspanin-
dependent pathway [10].
Most cells, including those grown in culture, are constantly
releasing exosomes. In immune cells, this response can be
enhanced by potent activation signals, such as antigenic,
cytokine or mitogen stimulation [11]. Upon stimulation of
the cell, MVBs polarize to the immunological synapse
within 10 min of engagement [12], and are released into the
extracellular environment by fusion with the plasma
membrane. The process of MVB docking at the plasma
membrane and subsequent fusion is regulated by Rab,
SNAP and SNARE proteins. The Rab27b and Rab27 effector
molecules, synaptotagmin-like 4 and exophilin 5, regulate
docking of the MVBs at the plasma membrane [13].
Meanwhile, Rab11 and Rab31 [13, 14], the R-SNARE
protein YKT6 [15], and the v-SNARE protein VAMP7/TI-
VAMP [16] are implicated in the fusion event between
MVBs and the plasma membrane. Rab27a has been shown
to play a role in both docking and fusion [13, 14].
Notably, it is plausible that some exosomes are released by
cells via direct outward budding and fission of the plasma
membrane, analogous to shedding microvesicles and
apoptotic blebs.
3. Exosome Cellular Recognition
While there is a large body of evidence relating to exosome
biogenesis, our understanding of exosome internalization
is in its infancy. Newer techniques such as fluorescent (Dil)-
labelling and the PolyParticleTracker programme are being
used to reveal the dynamics of exosomes during cellular
internalization [17]. Below is a discussion of the current
data on exosome internalization.
3.1 Free Floating
Exosomes released from cells circulate in body fluids at
least for a short period of time. Intravenous administration
of fluorescently labelled B cell-derived exosomes, via the
lateral tail vein of mice, revealed that the half-life of
exosomes in plasma was ~2 min [18]. However, exosomes
were detectable in the spleen up to 2 hrs later. Following
intranasal administration, exosomes have been found
within the brain and intestine after 3 hrs [19]. In both
studies, exosomes were found to co-localize with macro‐
phages, and did so within 15 min of administration [19].
The data suggest that exosomes are rapidly sequestered by
circulating monocyte/ macrophages in the liver and spleen,
though whether this is for clearance or cellular signalling
is unclear.
From intravital video microscopy of capillaries in the ears
of mice, in combination with computer modelling, it has
been estimated that nanoparticles of the exosome size range
(30–100 nm) randomly distribute within the blood vessel,
drifting laterally from the red blood cell core toward the
vessel wall where leukocytes localize [20]. This may
partially explain the systemic diffusion of exosomes to sites
distant from the secreting cells, and how exosomes may
come into contact with monocytes/macrophages, as well as
T cells. Similarly to liposomes, this could be mediated by
the opsonization of exosomes during circulation [21].
Phosphatidylcholine—hydrolysed to lysophatidylcholine
by calcium-independent phospholipase A2 (iPLA2) on the
surface of exosomes from rat reticulocytes—binds natural
IgM antibodies and complement component C3, promot‐
ing phagocytosis [22]. Other opsonins present on the
surface of exosomes, including phosphatidylserine and
lactoadherin (MFG-E8) [23], may explain the co-localiza‐
tion of exosomes with macrophages noted in abovemen‐
tioned studies [18, 19]. While T cells are not
considered ”professional” phagocytes, γδ T cells can
phagocytose bacteria and synthetic beads via antibody
opsonization and FcγRIII receptors [24].
An alternative explanation could be that exosomes use
chemokines to attract leukocytes to their location. Exo‐
somes express an impressive array of chemokines, which
may attract T cells and other cell types [25]. These include
CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CCL28, CXCL1,
CXCL2, and CXCL16. Of these, CCL2, CCL5, CCL20, and
CXCL16 are potent T cell chemoattractants.
3.2 Adhesion
A fundamental step for exosome-T cell communication is
adhesion. Lymphocyte adhesion by exosomes requires the
conformational change of integrins from a low to a high
affinity status. This enables oligomerization of integrins and
coupling with cytoskeletal elements, to facilitate the high
avidity binding of the lymphocyte to the integrin-bound
exosome [26]. The presence of ICAM-1 (CD54) on mature
DC-derived exosomes is critical for efficient naive T cell
priming, mediated by the leukocyte integrin LFA-1 (CD11a/
CD18 or αLβ2) [27]. Other integrins that have demonstrat‐
ed roles in exosomes-leukocyte adhesion are integrins β1
(CD29), α3 (CD49c) and αv (CD51), and lactadherin and
vitronectin, which are ligands for αvβ3/β5 integrins [9, 28,
29].  While the initial  binding/docking of T cells  to exo‐
somes is regulated by ICAM-1/LFA-1 [30], firm adhesion is
further facilitated via αL (CD11a), α4 (CD49d), CD44 and
ICAM-1 expression on leukocytes, and the expression of
tetraspanins CD9 and CD81 on exosomes [29, 31].
Tetraspanins are highly conserved through evolution and
have a role in adhesion, motility, signal transduction and
cell  activation.  A  number  of  tetraspanins  have  been
reported  on  the  surface  of  exosomes,  including  CD9,
CD53,  CD63,  CD81  and  CD82,  although  the  combina‐
tion and proportion of exosomes expressing a particular
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tetraspanin differs depending on the cell of origin. One
example  is  the  abovementioned  observation  that  only
~50% of exosomes from activated platelets express CD63
[32].  Tetraspanins  form  heterobimolecular  complexes
with integrins (e.g., α3β1) [33], Ig superfamily members
(e.g.,  ICAM-1, MICA, MICB) and co-receptor molecules
(e.g.,  CD4, CD8, CD19, CD21) [26, 34, 35].  It  is thought
that the expression of tetraspanins on exosomes contrib‐
utes to the spatial assembly for antigen recognition and
may  partially  dictate  the  signal  induced  by  the  exo‐
some. For example,  TCR co-stimulation via CD9 result‐
ed  in  only  partial  T  cell  activation  before  the  T  cell
underwent apoptosis, while traditional co-stimulation via
CD28 leads to the proliferation of T cells [36].
Other adhesion proteins are demonstrated to play a role in
the capture of exosomes, including CD169 (sialoadhesin)
on macrophages [18], and heparin sulfate proteoglycans on
both U-87 MG glioblastoma cells [37] and 293T human
embryonic kidney cells [38], while the latter may also bind
cytotoxic and/or helper T cells.
3.3 Antigen Recognition
To date, molecular profiling and proteomic analysis has
demonstrated that target cell specificity for exosomes
appears to be dictated solely by a combination of antigen
and MHC class I (Tc cells) and II molecules (CD4+ T cells)
[39]. The expression of MHC molecules on exosomes is
dependent on the expression of the molecule on the parent
cell. While the microRNAs contained in some exosomes
differ greatly to those of the parent cell [12, 40], the expres‐
sion of MHC class I and II molecules is similar to that of the
originating cell [41].
The expression of MHC class I molecules on exosomes
induces a negative signal via inhibitory receptors on the
recipient cell, such as ILT2, ILT4 and KIR2DL4, which
promote the inhibition of CD8+ Tc cells and NK cell
responses. MHC class I molecules are often found on
exosomes in conjunction with other immune modulating
molecules, such as the B7 molecules CD274 (B7H-1) and
CD276 (B7-H3) [42], and the MHC class I-related molecules
MICA and MICB, which down-regulate the NK cell-
activating molecule NKG2D on immune cells [43]. Exo‐
somes expressing HLA-G1 are secreted by melanoma cells
[44], and may play a role in immune evasion, which enables
escape from the immune response.
MHC class II molecules evoke a stimulatory signal and
promote the proliferation and differentiation of CD4+ T
cells. Exosomes from antigen-presenting cells such as DCs
and B lymphocytes express MHC class II. Exosomes
bearing HLA-DR1–haemagglutinin (306–318) complexes
weakly activate HA/DR1-specific T cells; however, the
incubation of HLA-DR1+ exosomes with DCs resulted in
highly efficient stimulation of antigen-specific T cells [45].
It remains to be seen whether there is another as-yet-
unidentified mechanism of cell targeting by exosomes.
4. Exosome Internalization
It is still unclear as to whether exosomes must be internal‐
ized by immune and non-immune cells in order to elicit
cellular responses. For example, cellular responses elicited
by RNA species rely on internalization. By comparison,
cellular responses induced by membrane-bound or soluble
FasL and TRAIL from exosomes do not require internali‐
zation, but are dependent on location and temporary
adhesion for juxtacrine or soluble signalling. Equally,
differing opinions as to the method by which exosome
internalization occurs—either by fusion, receptor-mediat‐
ed endocytosis, macropinocytosis or phagocytosis—exists
within the literature. However, the latter two methods may
represent mechanisms for the clearance of exosomes, rather
than the elicitation of a cellular response. A summary of the
internalization mechanisms for exosomes, and some of the
key proteins involved, is provided in Figure 1.
4.1 Soluble and Juxtacrine Signalling
Soluble signalling involves the proteolytic cleavage of
ligands from the exosomal surface or alternative splicing,
while juxtacrine signalling requires the juxtaposition of
ligands and receptors on the surfaces of the exosome and
target cell. Membrane-bound FasL, TRAIL and TNF can be
cleaved by metalloproteinases to form soluble cytokines.
Nevertheless, it should be noted that the death ligands,
soluble FasL and TRAIL, have a reduced pro-apoptotic
activity when compared to that of the membrane-bound
form [46, 47]. Exosomes from cultured placental explants
or plasma from pregnant women have FasL and TRAIL on
their membrane, and induce apoptosis in Jurkat T cells, via
NF-κB, CD3ζ and JAK3 down-regulation [48–50] [Sharon
McCracken, unpublished findings]. The same mechanism
has been demonstrated for exosomes derived from tu‐
mours [51].
4.2 Fusion
Vesicle-cell fusion is the process by which a vesicle merges
with the plasma membrane of a cell. Using a fluorescent
lipid-mixing assay and membrane fusion assay, monocyte-
derived microvesicles were demonstrated to bind and fuse
with the plasma membrane of activated platelets, and to
transfer proteins to the recipient cell, such as tissue factor
and P-selectin glycoprotein ligand-1 (PSGL-1) [52]. In a
similar experiment, exosomes from metastatic melanoma
cells fused with the plasma membrane, which could have
been inhibited by filipin [53]. Proteins were found to have
a minor, possibly structural, role during fusion. Co-
localization of exosomes with Rab53 or Lamp-1 suggested
that exosomes are internalized and interact with cytoplas‐
mic vesicles [53].
Unlike endocytosis, in which multiple mechanistic path‐
ways have been detailed, the mechanism of cell-cell fusion
is incompletely understood. The phenomenon may be
regulated by tetraspanin complexes on target cells. Tetra‐
spanins have a role in T cell activation and membrane
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fusion between sperm-oocyte [54, 55], myoblasts [56],
mononuclear phagocytes [57] and mammalian viral-cell
fusion [58].
While tetraspanin CD81, which co-localizes with CD4, has
been shown to be involved in exosome release from HIV-
infected T cells [59, 60], it has not yet been demonstrated
whether tetraspanins are involved in exosome-T cell
fusion. In the context of viral-cell fusion, tetraspanins
inhibit cell fusion; CD9, CD63, CD81, CD82, CD151 and
CD231 reduce HIV infection [61, 62] by inhibiting cell
fusion [63, 64] and cell-cell transmission of viral particles
[65]. The inhibition of cell-cell fusion of mononuclear
phagocytes by CD9 and CD81 has also been reported [57].
Whether this is also true in the context of exosome-cell
fusion remains to be seen.
It also seems plausible that, in a similar manner to leuko‐
cyte transendothelial migration, integrins are involved in
exosome  adhesion/attachment  to  the  target  cell,  and
following  this,  tetraspanin-enriched  microdomains
facilitate exosome fusion, which is alluded to in previous
reports [66, 67].
4.3 Phagocytosis
Phagocytosis is an actin-mediated mechanism which
requires the presence of specific opsonin receptors (i.e., FcR
and complement receptors), scavenger receptors or toll-like
receptors (Figure 1). While phagocytosis is typically
performed by “professional phagocytes” such as macro‐
phages and DCs, it can also be performed by “non-
professional” cells, including γδ T cells [24]. Phagocytosis
has been proposed as a means of exosome internalization.
Not surprisingly, monocytic/macrophagic cell lines were
able to internalize exosomes derived from erythroleukae‐
mia (K562) and T cell leukaemia (MT4) cells more efficient‐
ly than ”non-professional” phagocytic cells, including
Jurkat T cells and 293T human embryonic kidney cells [68].
The phagocytosis of exosomes was shown to be dependent
on the actin cytoskeleton, phosphatidylinositol 3-kinase
(PI3K), and dynamin2 [68]. Notably, actin, PI3K and
dynamin2 have all been implicated in both clathrin-
mediated endocytosis [69], and phagocytosis [70]. Internal‐
ized exosomes co-localized with Lamp-1,
lysobisphosphatidic acid and Rab7 [68] in late autophago‐
Figure 1. Schematic of exosome biogenesis, internalization and cellular response. The adhesion of exosomes to the recipient cell utilizes the interaction of
various exosomal surface proteins and cellular receptors. Once bound, the exosome may (i) elicit transduction of the signal via intracellular signalling pathways
and be released (juxtacrine signalling); (ii) fuse with the cellular membrane transferring protein and genetic contents, into the cytoplasm of the recipient cell
(fusion); or (iii) be endocytosed via phagocytosis, macropinocytosis or receptor-mediated endocytosis. This figure was produced using Servier Medical Art, available
from www.servier.com/Powerpoint-image-bank.
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somes and/or endosomal and lysosomal vesicles [71].
Determining whether phagocytosis represents a true
method of exosome internalization for the purpose of
intercellular communication, or is merely a means of
elimination, requires further research.
4.4 Macropinocytosis
During macropinocytosis, plasma membrane protrusions
driven by actin filaments form an invagination which non-
specifically endocytoses extracellular fluid and small
particles. Reportedly, phosphatidylserine (PtdSer; Figure
1) on the surface of oligodendrocyte-derived exosomes
activated macropinocytosis in a subset of microglia/
macrophages without antigen-presenting capability [72].
Macropinocytosis of exosomes is dependent on Na+ and
PI3K, with the inhibition of Na+-H+ ion exchange and PI3K
activity by the pharmacological inhibitors EIPA and
LY294002, respectively, reducing exosome uptake [73].
4.5 Receptor- and Raft-mediated Endocytosis
As the names suggest, receptor-mediated endocytosis and
raft-mediated endocytosis require either a ligand on the
exosomal surface to engage specific receptors on the
cellular plasma membrane, or the presence of cholesterol-
and sphingolipid-rich microdomains in the plasma mem‐
brane, respectively. The former, also called clathrin-
mediated endocytosis, utilizes clathrin and adaptor protein
2 complexes which coat the membrane and induce the
invagination of the membrane into a vesicle. The latter
includes caveolae-mediated endocytosis, as well as the
clathrin- and caveolae-independent endocytosis mecha‐
nisms RhoA-, CDC42-, and ARF6- regulated endocytosis,
which utilize distinct combinations of dynamin, flotillin
and/or Rab proteins [74]. The endocytosis of particles from
the external environment or plasma membrane may be sent
to lysosomes for degradation, or recycled back to the
plasma membrane.
Exosomes released from cultured rat adrenal gland
medulla (PC12) tumours are partially internalized by
clathrin-mediated endocytosis, as demonstrated using
pharmacological reduction (CPZ) and siRNA knockdown
of clathrin [73]. In another report, the internalization of
glioblastoma-derived exosomes involved non-classical,
lipid raft-dependent endocytosis, and required ERK1/2-
HSP27 signalling [75]. In this pathway, the negative
regulation of ERK1/2 by caveolin-1 inhibited exosome
endocytosis.
5. Exosome Intercellular Trafficking and Cellular
Response
A wide range of stimulatory or inhibitory functional
outcomes are shown to be induced following cellular
interactions with exosomes, including proliferation,
angiogenesis, apoptosis, cytokine production, immune
system modulation, and invasion or metastasis. Whether
or not a cellular response is elicited by the target cell likely
depends on the mechanism of internalization.
Soluble, juxtacrine and fusion are most likely to end with a
cellular response, as they do not directly engage the
endosomal-lysosomal degradative pathway. Phagocytosis
inevitably results in the fusion of the phagosome with
lysosomes and the degradation of its contents.
The endocytosis of exosomes, whether by macropinocyto‐
sis, or receptor- or raft-mediated mechanisms, always
results in the delivery of the vesicular cargo to the endoso‐
mal pathway. Early endosomes act as the sorting compart‐
ment. Those sent to late endosomes are then
unidirectionally sent for degradation by fusion with
lysosomes; meanwhile some proteins and fluids may be
redirected back to the plasma membrane via recycling
endosomes. However, even those sent to the late endosome
may escape degradation by the trans-Golgi network.
It is suggested that the macropinocytotic clearance of
exosomes by cells lacking an antigen-presenting capability
may represent a mechanism for the degradation of the
cellular membrane by immune cells in an immunologically
'silent' manner [72]. This implicates macropinocytosis as a
mechanism of exosomal clearance rather than cell signal‐
ling. Thus, exactly which of these mechanisms represent
bona fide mechanisms for exosome signalling and elicit a
cellular response, and which are mechanisms of exosome
clearance, needs to be delineated.
The internal transport network of phagosomes, macropi‐
nosomes, clathrin-coated vesicles and caveosomes requires
a spectrum of cellular components. As an example,
exosomes from chronic myeloid leukaemia cells were
shown to require v-SNARE protein VAMP3/cellubrevin for
the fusion of endosomes with autophagosomes [16], while
VAMP7/TI-VAMP was required for fusion between the
amphisome and lysosome. Similar dynamics of diffusion
on the plasma membrane and internalization have been
observed for natural and synthetic viruses [76, 77]. The
internalization of exosomes from glioblastoma cells was
dependent on ERK1/2 and HSP27 signalling [75]. Not
surprisingly, intracellular filamentous actin [78] and
microtubules [79] are also critical for the transport of
exosome-containing vesicles within the cell following
internalization.
Whether other cellular proteins known to be involved in
endosomal transport—such as p38α, PKCδ, arrestins and
syntaxins—are utilized when exosomes are internalized
remains to be demonstrated.
6. Exosomes, T Cells and Therapy
Since exosomes are naturally present in the circulation of
all individuals, and elicit effects that alter cellular function‐
ing, they present a possible therapy in many disease
settings. Molecular profiling and the functional analysis of
tumour-derived exosomes show that they express death
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ligands and mediate apoptosis of CD8+ T cells (for a recent
review, see [2]), while DC-derived exosomes promote
CD4+ T cell proliferation and regulate T cell responses [80].
Placenta-derived exosomes regulate both functional
characteristics, including mediating apoptosis, and induc‐
ing the proliferation and generation of regulatory T cells
(Tregs) [48]. Yet the question remains as to what signals are
required to elicit the desired therapeutic effect.
Manipulating the signals on the surface of exosomes or the
mRNA/microRNA content of exosomes seems most
plausible and has precedents. IL-10-treated exosomes from
bone marrow-derived DCs prevented the onset of murine
collagen-induced arthritis, and dampened the established
disease [81], in a model shown to be associated with a
robust and sustained T cell response to type II collagen [82].
Using this same model, exosomes derived from DCs
genetically engineered to produce IL-4 suppressed the
activity of T cells in vivo, via a MHC class II and FasL/Fas-
dependent mechanism [83].
The  reproducibility  of  using  cell  culture-derived  exo‐
somes for therapy remains an issue. The proteomic profil‐
ing of three independent batches of exosomes, from cultured
human embryonic stem cell-derived mesenchymal stem
cells (huES9.E1), identified ~400 unique proteins; howev‐
er,  only 154 proteins  (~20%) were common to all  three
preparations [84]. Thus, the use of manipulated cultures to
generate exosomes may result in a vast diversity of exo‐
some protein and RNA content. With the relative success of
lipid- and polymer-based nanomedicines, the extrapola‐
tion of the technology utilized for the extrusion, purifica‐
tion, analysis and labelling of these vesicles would most
likely be required to generate therapeutic exosomes [21].
While this review updates what is currently known about
the proteins involved in the interaction of (primarily) T cells
with exosomes, and their internalization, further elucida‐
tion of these mechanisms is required, focusing on what
governs the internalization mechanism used, and the signal
transduction pathways leading to cellular responses. Once
this is known, the therapeutic capability of exosomes is
potentially limitless!
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